Molecular biology of Hepatitis C infection

Liver Transplantation

Volumn 6, Issue 4, 2000, Pages 396-406

  Drazan, Kenneth E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; ENVELOPE PROTEIN; RIBAVIRIN; VIRUS PROTEIN; VIRUS RECEPTOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; HEPATITIS C; HEPATITIS C VIRUS; LIFE CYCLE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0033943728     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2000.6449     Document Type: Article

References (106)

1. Hepatitis C: Public health strategies
2. Hepatitis C and liver transplantation
3. Anticipated mortality of hepatitis C and impact on treatment [abstract]
4. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome
5. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
6. Hepatitis C Virus infection is associated with the development of hepatocellular carcinoma
7. Rising incidence of hepatocellular carcinoma in the United States
8. Pathology of hepatitis C virus infection
9. Cultivation of hepatitis C in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus
10. Infection of peripheral mononuclear blood cells by hepatitis C virus
11. The human bone marrow-derived B cell line CE, susceptible to hepatitis C virus infection
12. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line
13. Replication and multiplication of hepatitis C virus genome in human foetal liver cells
14. Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT-PCR
15. Evidence for consistent HCV replication in HepG2 cells
16. Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukaemia virus type I infected cell line, MT-2
17. Genetic analysis of the hepatitis C virus (HCV) genome from HCV-infected human T-cells
18. Posttransfusion non-A, non-B hepatitis, physicochemical properties of two distinct agents
19. Analysis of host viral interactions in CMV infections using cDNA microarray
20. Transmission of hepatitis C virus infection to tree shrews
21. Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: The Trimera system
22. Hepatitis C virus: Buoyant density of the factor VIII-derived isolate in sucrose
23. Determining the size of non-A, non-B hepatitis virus by filtration
24. Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes
25. Association of hepatitis C virus in human sera with b-lipoprotein
26. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins
27. Hepatitis C virus particle detected by immunoelectron microscopic study
28. The etiology of mixed cryoglobulinemia associated with hepatitis C virus infection
29. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro
30. A receptor-mediated pathway for cholesterol homeostasis
31. Calcium cages, acid baths and recycling receptors
32. Members of the low-density lipoprotein receptor family mediate cell entry of a minor group cold virus
33. A receptor for subgroup A sarcoma virus is related to the low-density lipoprotein receptor
34. Establishment of persistent hepatitis C virus infection and replication in vitro
35. CD81 (TAPA-1): A molecule involved in signal transduction and cell adhesion in the immune system
36. Binding of hepatitis C virus to CD81
37. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81
38. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection
39. Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: An emerging picture
40. Normal lymphocyte development but delayed humoral immune response in CD81-null mice
41. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
42. Characterization of the terminal regions of hepatitis C viral R.N.A.: Identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end
43. Internal ribosomal entry site within hepatitis C virus RNA
44. Secondary structure of the 5' nontranslated regions of the hepatitis C virus and pestivirus genomic RNAs
45. Sequence analysis of the 5' non-coding region of hepatitis C virus
46. HCV genotyping by three methods: Analysis of discordant results based on sequencing
47. Internal ribosome entry sites within the RNA genomes of hepatitis C virus and other flaviviruses
48. Starting at the beginning, middle and end: Translation initiation in eukaryotes
49. Cellular factors in the transcription and regulation of viral RNA genomes: A parallel to DNA-dependent RNA transcription
50. Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites
51. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis
52. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus
53. Biosynthesis and biochemical properties of the hepatitis C virus core protein
54. Suppression of host immune response by the core protein of hepatitis C virus: Implications for hepatitis C virus persistence
55. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in Huh-7 cells
56. Hepatitis C virus core protein inhibits human immunodeficiency virus type 1 replication
57. Transcriptional repression of P53 promoter by hepatitis C virus core protein
58. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-β receptor
59. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets
60. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins
61. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorometric assessment of envelope glycoprotein 2 binding to target cells
62. Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection
63. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient
64. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus block viral attachment
65. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures
66. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
67. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
68. The NS2 protein of hepatitis C virus is a transmembrane polypeptide
69. Hepatitis C virus NS3/4A protease
70. Multiple enzymatic acuvities associated with recombinant NS3 protein of hepatitis C virus
71. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3)
72. NS3-4A of hepatitis C virus is a chymotrypsin-like protease
73. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred with amino acid and substitutions in the NS5A gene
74. Mutations in the nonstructural protein NS5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
75. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
76. Control of PKR protein kinase by the hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
77. Role of the double-stranded RNA-activated protein kinase (PKR) in cell regulation
78. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance
79. PKR, apoptosis and cancer
80. Translational control: The cancer connection
81. Primary structural comparison of RNA-dependent polymerases from plant, animal and bacterial viruses
82. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA
83. HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitness
84. Structure of the 3' terminus of the hepatitis C virus genome
85. Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA
86. In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone
87. Treatment of chronic hepatitis C with recombinant interferon-alfa. A multicenter randomized controlled trial
88. Combination antiviral therapy with ribavirin and interferon alpha in interferon alpha relapsers and non-responders: Italian experience
89. Therapy of hepatitis C: Overview
90. The 2-5A system in viral infection and apoptosis
91. When two strands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA
92. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alfa therapy
93. The clinical pharmacology of ribavirin
94. Strategies for antiviral drug discovery
95. Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides
96. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes
97. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
98. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity
99. Poly(U) binding activity of hepatitis C virus NS3 protein, a putative RNA helicuse
100. Use of a prenylarion inhibitor as a novel antiviral agent
101. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
102. The Trimera Mouse System: A model for HCV infection and evaluation of antiviral drugs
103. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: Comparison with reported isolates for conserved and divergent regions